• Messori A. Synthetizing Published Evidence on Survival by Reconstruction of Patient-Level Data and Generation of a Multi-Trial Kaplan-Meier Curve. Cureus. 2021;13(11):e19422. Published 2021 Nov 9. doi:10.7759/cureus.19422

• Trippoli S, Di Spazio L, Chiumente M, Messori A. Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method. Cureus. 2022;14(2):e22645. Published 2022 Feb 27. doi:10.7759/cureus.22645

• Di Spazio L, Rivano M, Cancanelli L, Chiumente M, Mengato D, Messori A. The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors. Cureus. 2022;14(1):e21065. Published 2022 Jan 9. doi:10.7759/cureus.21065
• Messori A, Rivano M, Mengato D, Cancanelli L, Di Spazio L, Chiumente M. A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2022;63(5):1261-1264. doi:10.1080/10428194.2021.2022141

• Messori A. Lutetium in prostate cancer: Reconstruction of patient-level data from published trials and generation of a multi-trial Kaplan-Meier curve. World J Methodol. 2022;12(3):107-112. Published 2022 May 20. doi:10.5662/wjm.v12.i3.107

• Mengato D, Cancanelli L, Di Spazio L, Rivano M, Chiumente M, Messori A. Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy [published online ahead of print, 2022 Jun 2]. Int J Clin Pharmacol Ther. 2022;10.5414/CP204243. doi:10.5414/CP204243

• Ossato A, Damuzzo V, Baldo P, Mengato D, Chiumente M, Messori A. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data [published online ahead of print, 2022 Aug 3]. Cancer Med. 2022;10.1002/cam4.5067. doi:10.1002/cam4.5067
• Rivano M, Cancanelli L, Di Spazio L, Mengato D, Chiumente M, Messori A. Survival with novel hormonal therapies in patients with nonmetastatic castration-resistant prostate cancer:indirect comparison of three randomized phase III trials [published online ahead of print, 2022 Sep 9]. World J Urol. 2022